Prix Galien 2012 nomination for the ONCO-3CLA

The ONCO-3CLA project aims to develop therapies based on the concept of a “magic bullet” created in the 19th century by Paul Erlich, a German pioneer of chemotherapy.  The idea is to create biotechnological prodrugs that selectively identify and destroy cancer cells.  A number of patent filings have already been made. 

Maciej Adamkiewicz, President of the Adamed Group: I am very proud and grateful to be the only Polish company among the group of nominees for the Prix Galien award.  A special thanks to everyone involved in research and development at our company.  I would like to thank the whole R&D team as well as the outstanding researchers and employees of the research centers that we work with on the ONCO-3CLA project. We would not have been able to achieve all of this without the passion, engagement and hard work of the whole team. We are glad yet we are also well aware of the hard work that still awaits us.

For more than 40 years in dozens of countries around the world, various institutions, organizations and companies compete each year for the Prix Galien. The prize is awarded in recognition for breakthrough achievements in the area of pharmaceuticals and medicine. The competition is organized every year in twelve countries: France, Spain, United Kingdom, Germany, The Netherlands, Belgium, Luxembourg, Portugal, Switzerland, Italy, USA and Canada. In 2012 for the first time ever it was also held in Poland.